Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scDEC-CEA adenovirus
- Development stage
- Preclinical
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
scDEC-CEA adenovirus (Ad scDEC-CEA-GFP) is an experimental recombinant adenoviral vector designed for cancer immunotherapy. The construct encodes a fusion protein consisting of the carcinoembryonic antigen (CEA) and a single-chain variable fragment (scFv) that specifically targets the DEC205 receptor (CD205) on dendritic cells. By directing the tumor-associated antigen (CEA) specifically to dendritic cells, the vector aims to enhance antigen uptake, processing, and subsequent presentation to T cells, thereby stimulating a potent and specific anti-tumor immune response. This research-stage biologic has been investigated in preclinical mouse models for its potential efficacy against CEA-expressing malignancies, such as colorectal and lung cancers.
- Other names
- Ad-scDEC-CEAscDEC-CEA adenoviral vector
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)LY75 (Dendritic cell receptor DEC–205)
Beyond the preview
Go deeper on scDEC-CEA adenovirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on scDEC-CEA adenovirus.